Estrogen alters amyloid precursor protein as well as dendritic and cholinergic markers in a mouse model of Down syndrome - PubMed (original) (raw)
Estrogen alters amyloid precursor protein as well as dendritic and cholinergic markers in a mouse model of Down syndrome
Ann-Charlotte Granholm et al. Hippocampus. 2003.
Abstract
Individuals with Down syndrome (DS) develop the pathological hallmarks of Alzheimer's disease at an early age, later followed by memory decline and dementia. Women with DS are twice as likely to undergo early menopause, and levels of estradiol correlate with onset of cognitive decline in these women. We have demonstrated that a mouse model of DS, mice with segmental trisomy of chromosome 16 (Ts65Dn), develop a significant deficit in both reference and working memory as young adults (6-10 months of age), coupled with phenotypic loss of cholinergic neurons in the basal forebrain and altered growth factor levels. In the present study we examined cholinergic and dendritic markers in the hippocampal formation and levels of the amyloid precursor protein (APP) in different brain regions of Ts65Dn mice treated with estradiol for 60 days. The density of the dendritic marker Map2 was significantly decreased in the hippocampal formation of middle-aged trisomic mice (9-15 months old), and the density of cholinergic neurites (acetylcholinesterase [AChE] histochemistry) was also decreased in specific layers of the hippocampus. Treatment with 17beta-estradiol alleviated the decreases in Map2 and AChE staining, but had no effect on full-length APP levels in the hippocampus. In contrast, a main effect of treatment on APP levels in the striatum was noted, with significant elevations observed in controls and trisomics. These findings demonstrate that estrogen can alleviate deficits in cholinergic and dendritic elements in the hippocampal formation and further strengthens the rationale to explore estrogen replacement therapy in women with DS.
Similar articles
- Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome.
Hunter CL, Isacson O, Nelson M, Bimonte-Nelson H, Seo H, Lin L, Ford K, Kindy MS, Granholm AC. Hunter CL, et al. Neurosci Res. 2003 Apr;45(4):437-45. doi: 10.1016/s0168-0102(03)00005-1. Neurosci Res. 2003. PMID: 12657457 - Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen.
Hunter CL, Bimonte-Nelson HA, Nelson M, Eckman CB, Granholm AC. Hunter CL, et al. Neurobiol Aging. 2004 Aug;25(7):873-84. doi: 10.1016/j.neurobiolaging.2003.10.010. Neurobiol Aging. 2004. PMID: 15212841 - Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.
Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, Xia W, Villar A, Campbell WA, Kulnane LS, Nixon RA, Lamb BT, Epstein CJ, Stokin GB, Goldstein LS, Mobley WC. Salehi A, et al. Neuron. 2006 Jul 6;51(1):29-42. doi: 10.1016/j.neuron.2006.05.022. Neuron. 2006. PMID: 16815330 - Drug discovery: estrogen-related compounds in mouse models of Alzheimer's disease.
Smith JD, Chakrabarti E, Levin-Allerhand JA. Smith JD, et al. J Mol Neurosci. 2004;24(1):145-7. doi: 10.1385/JMN:24:1:145. J Mol Neurosci. 2004. PMID: 15314263 Review. - Action of estrogen on survival of basal forebrain cholinergic neurons: promoting amelioration.
Abrahám IM, Koszegi Z, Tolod-Kemp E, Szego EM. Abrahám IM, et al. Psychoneuroendocrinology. 2009 Dec;34 Suppl 1:S104-12. doi: 10.1016/j.psyneuen.2009.05.024. Psychoneuroendocrinology. 2009. PMID: 19560872 Review.
Cited by
- Sex Differences in Brain Disorders.
Ziemka-Nalecz M, Pawelec P, Ziabska K, Zalewska T. Ziemka-Nalecz M, et al. Int J Mol Sci. 2023 Sep 26;24(19):14571. doi: 10.3390/ijms241914571. Int J Mol Sci. 2023. PMID: 37834018 Free PMC article. Review. - The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy.
Do Carmo S, Kannel B, Cuello AC. Do Carmo S, et al. Cells. 2021 Dec 22;11(1):16. doi: 10.3390/cells11010016. Cells. 2021. PMID: 35011577 Free PMC article. Review. - Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.
Alldred MJ, Chao HM, Lee SH, Beilin J, Powers BE, Petkova E, Strupp BJ, Ginsberg SD. Alldred MJ, et al. FASEB J. 2019 Sep;33(9):9871-9884. doi: 10.1096/fj.201802669RR. Epub 2019 Jun 10. FASEB J. 2019. PMID: 31180719 Free PMC article. - CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.
Alldred MJ, Chao HM, Lee SH, Beilin J, Powers BE, Petkova E, Strupp BJ, Ginsberg SD. Alldred MJ, et al. Hippocampus. 2018 Apr;28(4):251-268. doi: 10.1002/hipo.22832. Epub 2018 Feb 12. Hippocampus. 2018. PMID: 29394516 Free PMC article. - Rodent models in Down syndrome research: impact and future opportunities.
Herault Y, Delabar JM, Fisher EMC, Tybulewicz VLJ, Yu E, Brault V. Herault Y, et al. Dis Model Mech. 2017 Oct 1;10(10):1165-1186. doi: 10.1242/dmm.029728. Dis Model Mech. 2017. PMID: 28993310 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical